<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00953056</url>
  </required_header>
  <id_info>
    <org_study_id>V260-028</org_study_id>
    <secondary_id>2009_627</secondary_id>
    <nct_id>NCT00953056</nct_id>
  </id_info>
  <brief_title>A Study of V260 in Healthy Chinese Adults, Children and Infants (V260-028)(COMPLETED)</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Safety and Tolerability Study of Live Pentavalent Human-Bovine Reassortant Rotavirus Vaccine in Chinese Healthy Adults, Children and Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and tolerability of RotaTeq™ (V260) in the healthy Chinese
      populations. Approximately 144 participants will be enrolled and equally stratified into
      three age cohorts, Cohort I ages 19-47 years, Cohort II ages 2-6 years, and Cohort III ages
      6-12 weeks. Randomization ratio is 1:1 in each cohort. The study will be conducted
      sequentially, participants in Cohort I then Cohort II receiving 1 dose of, and then
      participants in Cohort III receiving 3 doses of RotaTeq™/placebo. The primary investigator
      and the Ethics Review Committee will review blinded safety data and make decision based on
      their best clinical judgment to move study forward between cohorts. Duration for the entire
      study will be approximately 6-9 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Serious Adverse Events</measure>
    <time_frame>up to 14 days post vaccination</time_frame>
    <description>All serious adverse events (SAEs) were collected for 14 days following each dose to obtain the number of participants with serious adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Serious Adverse Events</measure>
    <time_frame>14 days post vaccination</time_frame>
    <description>The total number of serious adverse experiences (events) in participants up to 14 days post vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Infants With Fecal Vaccine Virus Shedding</measure>
    <time_frame>Between Day 3 and Day 7 following each of 3 doses of RotaTeq™/placebo</time_frame>
    <description>Fecal shedding of vaccine rotavirus in Cohort III (infants) was evaluated by determining the number of participants whose stool was positive by both (1) the Enzyme-linked Immunosorbent Assay (EIA) to detect the rotavirus antigen, and (2) PCR VP6 Genotyping (a polymerase chain reaction assay specific for rotavirus genome 6, coding for the VP6 protein of the vaccine virus). For analysis, two stool samples were collected per participant on separate days between Day 3 and Day 7 following each vaccination dose.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">144</enrollment>
  <condition>Rotavirus Gastroenteritis</condition>
  <arm_group>
    <arm_group_label>Cohort I - RotaTeq™, Adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adults randomized to receive a single dose of RotaTeq™.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort I - Placebo, Adults</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Adults randomized to receive a single dose of matching placebo to RotaTeq™.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort II - RotaTeq™, Children</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children randomized to receive a single dose of RotaTeq™.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort II - Placebo, Children</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Children randomized to receive a single dose of matching placebo to RotaTeq™.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort III - RotaTeq™, Infants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants randomized to receive 3 doses of RotaTeq™.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort III - Placebo, Infants</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Infants randomized to receive 3 doses of matching placebo to RotaTeq™.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rotavirus Vaccine, Live, Oral, Pentavalent</intervention_name>
    <description>Single 2.0 mL dose V260 (RotaTeq™) administered orally at enrollment.
The 2-mL vaccine consists of an oral solution of 5 live human-bovine reassortant rotaviruses.</description>
    <arm_group_label>Cohort I - RotaTeq™, Adults</arm_group_label>
    <arm_group_label>Cohort II - RotaTeq™, Children</arm_group_label>
    <other_name>V260, RotaTeq™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>Single 2.0 mL dose of matching placebo to RotaTeq™ administered orally at enrollment.</description>
    <arm_group_label>Cohort I - Placebo, Adults</arm_group_label>
    <arm_group_label>Cohort II - Placebo, Children</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rotavirus Vaccine, Live, Oral, Pentavalent</intervention_name>
    <description>Three 2.0 mL doses of RotaTeq™ administered orally at 3 separate visits scheduled 28 to 70 days apart. The third dose was administered by 32 weeks of age.
The 2-mL vaccine consists of an oral solution of 5 live human-bovine reassortant rotaviruses.</description>
    <arm_group_label>Cohort III - RotaTeq™, Infants</arm_group_label>
    <other_name>V260, RotaTeq™.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>Three 2.0 mL doses of matching placebo to RotaTeq™ administered orally at 3 separate visits scheduled 28 to 70 days apart. The third dose was administered by 32 weeks of age.</description>
    <arm_group_label>Cohort III - Placebo, Infants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults ages 19 to 47 years for Cohort I

          -  Healthy children ages 2 to 6 years for Cohort II

          -  Healthy infants ages 6 to 12 weeks for Cohort III

          -  Negative pregnancy test for females in Cohort I

          -  Signed Informed Consent Forms (ICFs)

        Exclusion Criteria:

          -  Participants in Cohorts I and II receiving any vaccine 14 days before or anticipated
             after study vaccine

          -  Participants in Cohort III receiving non-concomitant live vaccines 14 days before or
             after study vaccine

          -  Prior administration of any rotavirus vaccine

          -  Elevated temperature, with axillary temperature ≥37.1 Degrees C 24 hours before study
             vaccine

          -  Prior or active gastrointestinal illnesses, immunodeficiency

          -  Any condition which may interfere with evaluation of study objectives or make
             participation in the study unsafe for the participant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>47 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>China</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2009</study_first_submitted>
  <study_first_submitted_qc>August 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2009</study_first_posted>
  <results_first_submitted>March 25, 2011</results_first_submitted>
  <results_first_submitted_qc>March 25, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 15, 2011</results_first_posted>
  <last_update_submitted>October 30, 2015</last_update_submitted>
  <last_update_submitted_qc>October 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroenteritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 144 participants were enrolled; 48 in each of 3 cohorts. This study was conducted sequentially in the 3 different Cohorts, Chinese adults (Cohort I) first, followed by children (Cohort II), and then infants (Cohort III).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort I - RotaTeq™, Adults</title>
          <description>Adults randomized to receive a single dose of RotaTeq™.</description>
        </group>
        <group group_id="P2">
          <title>Cohort I - Placebo, Adults</title>
          <description>Adults randomized to receive a single dose of matching placebo to RotaTeq™.</description>
        </group>
        <group group_id="P3">
          <title>Cohort II - RotaTeq™, Children</title>
          <description>Children randomized to receive a single dose of RotaTeq™.</description>
        </group>
        <group group_id="P4">
          <title>Cohort II - Placebo, Children</title>
          <description>Children randomized to receive a single dose of matching placebo to RotaTeq™.</description>
        </group>
        <group group_id="P5">
          <title>Cohort III - RotaTeq™, Infants</title>
          <description>Infants randomized to receive 3 doses of RotaTeq™.</description>
        </group>
        <group group_id="P6">
          <title>Cohort III - Placebo, Infants</title>
          <description>Infants randomized to receive 3 doses of matching placebo to RotaTeq™.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="24"/>
                <participants group_id="P6" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="22">One participant received placebo at the second dose in error, but completed the study.</participants>
                <participants group_id="P6" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Serious Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort I - RotaTeq™, Adults</title>
          <description>Adults randomized to receive a single dose of RotaTeq™.</description>
        </group>
        <group group_id="B2">
          <title>Cohort I - Placebo, Adults</title>
          <description>Adults randomized to receive a single dose of matching placebo to RotaTeq™.</description>
        </group>
        <group group_id="B3">
          <title>Cohort II - RotaTeq™, Children</title>
          <description>Children randomized to receive a single dose of RotaTeq™.</description>
        </group>
        <group group_id="B4">
          <title>Cohort II - Placebo, Children</title>
          <description>Children randomized to receive a single dose of matching placebo to RotaTeq™.</description>
        </group>
        <group group_id="B5">
          <title>Cohort III - RotaTeq™, Infants</title>
          <description>Infants randomized to receive 3 doses of RotaTeq™.</description>
        </group>
        <group group_id="B6">
          <title>Cohort III - Placebo, Infants</title>
          <description>Infants randomized to receive 3 doses of matching placebo to RotaTeq™.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="24"/>
            <count group_id="B5" value="24"/>
            <count group_id="B6" value="24"/>
            <count group_id="B7" value="144"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>The inclusion criterion for Cohort I (adults) in this study was 19-47 years. However, one participant who was 49 years at study entry was randomized.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>6 weeks to 12 weeks (infants)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years to 5 years (children)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>19 years to 49 years (adults)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="13"/>
                    <measurement group_id="B7" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Serious Adverse Events</title>
        <description>All serious adverse events (SAEs) were collected for 14 days following each dose to obtain the number of participants with serious adverse events.</description>
        <time_frame>up to 14 days post vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort I - RotaTeq™, Adults</title>
            <description>Adults randomized to receive a single dose of RotaTeq™.</description>
          </group>
          <group group_id="O2">
            <title>Cohort I - Placebo, Adults</title>
            <description>Adults randomized to receive a single dose of matching placebo to RotaTeq™.</description>
          </group>
          <group group_id="O3">
            <title>Cohort II - RotaTeq™, Children</title>
            <description>Children randomized to receive a single dose of RotaTeq™.</description>
          </group>
          <group group_id="O4">
            <title>Cohort II - Placebo, Children</title>
            <description>Children randomized to receive a single dose of matching placebo to RotaTeq™.</description>
          </group>
          <group group_id="O5">
            <title>Cohort III - RotaTeq™, Infants</title>
            <description>Infants randomized to receive 3 doses of RotaTeq™.</description>
          </group>
          <group group_id="O6">
            <title>Cohort III - Placebo, Infants</title>
            <description>Infants randomized to receive 3 doses of matching placebo to RotaTeq™.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events</title>
          <description>All serious adverse events (SAEs) were collected for 14 days following each dose to obtain the number of participants with serious adverse events.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Serious Adverse Events</title>
        <description>The total number of serious adverse experiences (events) in participants up to 14 days post vaccination.</description>
        <time_frame>14 days post vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort I - RotaTeq™, Adults</title>
            <description>Adults randomized to receive a single dose of RotaTeq™.</description>
          </group>
          <group group_id="O2">
            <title>Cohort I - Placebo, Adults</title>
            <description>Adults randomized to receive a single dose of matching placebo to RotaTeq™.</description>
          </group>
          <group group_id="O3">
            <title>Cohort II - RotaTeq™, Children</title>
            <description>Children randomized to receive a single dose of RotaTeq™.</description>
          </group>
          <group group_id="O4">
            <title>Cohort II - Placebo, Children</title>
            <description>Children randomized to receive a single dose of matching placebo to RotaTeq™.</description>
          </group>
          <group group_id="O5">
            <title>Cohort III - RotaTeq™, Infants</title>
            <description>Infants randomized to receive 3 doses of RotaTeq™.</description>
          </group>
          <group group_id="O6">
            <title>Cohort III - Placebo, Infants</title>
            <description>Infants randomized to receive 3 doses of matching placebo to RotaTeq™.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Serious Adverse Events</title>
          <description>The total number of serious adverse experiences (events) in participants up to 14 days post vaccination.</description>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants With Fecal Vaccine Virus Shedding</title>
        <description>Fecal shedding of vaccine rotavirus in Cohort III (infants) was evaluated by determining the number of participants whose stool was positive by both (1) the Enzyme-linked Immunosorbent Assay (EIA) to detect the rotavirus antigen, and (2) PCR VP6 Genotyping (a polymerase chain reaction assay specific for rotavirus genome 6, coding for the VP6 protein of the vaccine virus). For analysis, two stool samples were collected per participant on separate days between Day 3 and Day 7 following each vaccination dose.</description>
        <time_frame>Between Day 3 and Day 7 following each of 3 doses of RotaTeq™/placebo</time_frame>
        <population>Only participants in Cohort III, infants that received the scheduled dose of vaccination, and for whom the stool samples were available for testing, were included in the analysis for that dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort III - RotaTeq™, Infants</title>
            <description>Infants randomized to receive 3 doses of RotaTeq™.</description>
          </group>
          <group group_id="O2">
            <title>Cohort III - Placebo, Infants</title>
            <description>Infants randomized to receive 3 doses of matching placebo to RotaTeq™.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With Fecal Vaccine Virus Shedding</title>
          <description>Fecal shedding of vaccine rotavirus in Cohort III (infants) was evaluated by determining the number of participants whose stool was positive by both (1) the Enzyme-linked Immunosorbent Assay (EIA) to detect the rotavirus antigen, and (2) PCR VP6 Genotyping (a polymerase chain reaction assay specific for rotavirus genome 6, coding for the VP6 protein of the vaccine virus). For analysis, two stool samples were collected per participant on separate days between Day 3 and Day 7 following each vaccination dose.</description>
          <population>Only participants in Cohort III, infants that received the scheduled dose of vaccination, and for whom the stool samples were available for testing, were included in the analysis for that dose.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Postdose 1 (n=23 for RotaTeq™, n=24 for placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postdose 2 (n=21 for RotaTeq™, n=22 for placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postdose 3 (n=22 for RotaTeq™, n=20 for placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>One participant in the Cohort III-RotaTeq™ treatment group received RotaTeq™ at the first and third dose but placebo at the second dose in error. The participant had moderate or mild diarrhea after the second and third doses, respectively. The participant's AE data is included in the AE tables under the Cohort III-RotaTeq™ treatment group.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort I - RotaTeq™, Adults</title>
          <description>Adults randomized to receive a single dose of RotaTeq™.</description>
        </group>
        <group group_id="E2">
          <title>Cohort I - Placebo, Adults</title>
          <description>Adults randomized to receive a single dose of matching placebo to RotaTeq™.</description>
        </group>
        <group group_id="E3">
          <title>Cohort II - RotaTeq™, Children</title>
          <description>Children randomized to receive a single dose of RotaTeq™.</description>
        </group>
        <group group_id="E4">
          <title>Cohort II - Placebo, Children</title>
          <description>Children randomized to receive a single dose of matching placebo to RotaTeq™.</description>
        </group>
        <group group_id="E5">
          <title>Cohort III - RotaTeq™, Infants</title>
          <description>Infants randomized to receive 3 doses of RotaTeq™.</description>
        </group>
        <group group_id="E6">
          <title>Cohort III - Placebo, Infants</title>
          <description>Infants randomized to receive 3 doses of matching placebo to RotaTeq™.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>ENCEPHALITIS VIRAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="23" subjects_affected="13" subjects_at_risk="24"/>
                <counts group_id="E6" events="19" subjects_affected="8" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="22" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E6" events="25" subjects_affected="12" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="11" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E6" events="8" subjects_affected="5" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" events="4" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/ presentation. SPONSOR review can be expedited to meet publication guidelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp and Dohme</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

